Structured Administration and Supply Arrangement (SASA)

|  |  |
| --- | --- |
| **TITLE:** | **Treatment of Sexually Transmitted Infection by Aboriginal Health Practitioners** |

1. **Authority:**

Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

1. **Scope:**

Authorises Aboriginal Health Practitioners working in a public health program to administer doses of antibiotics for treatment of a sexually transmitted infection.

1. **Criteria:**

This SASA authorises the actions specified in the table below.

| Practitioner: | Aboriginal Health Practitioners who have completed training in accordance with Appendix 1. |
| --- | --- |
| Practice setting: | Public health programs operated or managed by a Health Service Provider of the WA Health system, or contracted entity, or a health service that is a member of the Aboriginal Health Council of Western Australia.  All regions of WA. |
| Approved activity: | Administration |
| Approved  medicines: | Medicines listed as approved treatments in Appendix 2:   * Oral azithromycin and ceftriaxone with lidocaine by deep intramuscular injection as a single treatment. * Oral azithromycin, amoxicillin and probenecid as a single treatment. * Oral azithromycin as a single treatment. * Benzathine benzylpenicillin by deep intramuscular injection as a single treatment. |
| Medical  conditions: | Sexually transmitted infections in adults and mature minors aged 14 years or older:   * chlamydia and/or gonorrhoea and/or syphilis confirmed by laboratory or point-of-care testing; * syphilis (excluding neurosyphilis) of less than 2 years duration, or unknown duration, confirmed by laboratory testing or indicated by a reactive point-of-care test; * empirical treatment of people presenting with symptoms consistent with infectious syphilis (excluding neurosyphilis) and/or uncomplicated urethritis and cervicitis syndromes consistent with chlamydia and/or gonorrhoea * asymptomatic people presenting as known contacts of a person confirmed with chlamydia and/or gonorrhoea and/or syphilis. |

1. **Conditions:**

The administration of approved medicines under this SASA is subject to the conditions that:

* 1. Patient selection, administration and follow up care is in accordance with the *Guidelines for managing sexually transmitted infections and blood-borne viruses* (The Silver Book) and Appendix 2;
  2. Administration is not repeated for the same instance of the condition, without the direction of a medical practitioner, credentialed for a public health STI program by a Health Service Provider of the WA Health system, or other entity under which this SASA is being applied.
  3. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder;
  4. Procurement and storage of the approved medicines is in accordance with Part 9 of the Medicines and Poisons Regulations 2016;
  5. Record keeping of administration is in accordance with Part 12 of the Medicines and Poisons Regulations 2016;
  6. Laboratory confirmed diagnosis of chlamydia and/or gonorrhea and/or syphilis must be notified to the Director, Communicable Disease Control Directorate, Department of Health, via the local Public Health Unit by post, telephone or facsimile, preferably within 24 hours; and,
  7. Notification must comply with the Procedure for Notification of Communicable Diseases (excluding HIV/AIDS) and be in an approved notification format.

1. **References:**
   1. *Guidelines for managing sexually transmitted infections and blood-borne viruses.* Available at*:* <http://ww2.health.wa.gov.au/Silver-book>
   2. Communicable Disease Control Directorate. *Notification of Communicable Diseases.* Availableat: <http://ww2.health.wa.gov.au/Silver-book/STI-or-HIV-notification>
2. **Issued by:**

|  |  |
| --- | --- |
| **Name:** | Dr Andrew Robertson |
| **Position:** | Chief Health Officer |
| **Date:** | 24 October 2024 |

|  |  |  |  |
| --- | --- | --- | --- |
| Enquiries to: | Medicines and Poisons Regulation Branch | Number: | 014/3-2024 |
|  | MPRB@health.wa.gov.au | Date: | 24 October 2024 |

**APPENDIX 1**

|  |
| --- |
| **Approved Training** |

All Aboriginal Health Practitioners administering a medicine in accordance with this SASA must have successfully completed a course of training approved by the Chief Executive Officer of the Department of Health or an equivalent course provided by a Registered Training Organisation (RTO) or a university and must maintain their competency through updates every two years.

Approved courses must require participants to demonstrate satisfactory knowledge, understanding and minimum competencies in the following areas:

1. Sexual health history taking;
2. Sexual health and STI clinical assessment;
3. Pathology testing, including request and collecting samples;
4. Contraindications and adverse effects of the medicines authorised for administration;
5. STI health promotion and education;
6. STI contact tracing;
7. Communicable disease notification and referral; and
8. Reporting of suspected child sexual abuse.

**APPENDIX 2**

|  |
| --- |
| **Approved treatments and treatment recommendations** |

**Approved treatments**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Treatment** | **Agent** | | **Dosage** | **Route** | **Frequency** |
| Azithromycin 1 gram | Azithromycin | | 1 gram | oral | single dose |
| Azithromycin 2 grams | Azithromycin | | 2 grams (1 gram x 2 doses) | oral | 1 gram, then another 1 gram 12 to 24 hours later2 |
| ZAP pack | Azithromycin | with  and | 1 gram | oral | single dose |
| Amoxicillin | 3 gram |
| Probenecid | 1 gram |
| LAC pack | Azithromycin | with | 1 gram | oral | single dose |
| Ceftriaxone with lidocaine 1% | 500 mg in 2 ml | deep intramuscular injection |
| Azithromycin + Ceftriaxone with lidocaine | Azithromycin | with | 2 grams | oral | single dose |
| Ceftriaxone with lidocaine 1% | 500 mg in 2 ml | deep intramuscular injection |
| Benzathine benzylpenicillin | Benzathine benzylpenicillin | | 2,400,000 units[[1]](#footnote-1) | deep intramuscular injection, 1,200,000 units on each side | single dose |

**Treatment recommendations**

|  |  |  |  |
| --- | --- | --- | --- |
| **Client** | | **STI acquired in** | **Treatment** |
| Empirical treatment of symptomatic clients | Uncomplicated urogenital gonorrhoea  + / - chlamydia | Goldfields, Kimberley | ZAP |
| Rest of WA and elsewhere | LAC |
| Infectious syphilis | Anywhere | Benzathine benzylpenicillin |
| Laboratory or Point-of-Care testing confirmed cases | Uncomplicated urogenital or rectal gonorrhoea | Goldfields, Kimberley | ZAP |
| Rest of WA and elsewhere | LAC |
| Uncomplicated pharyngeal gonorrhoea | Goldfields, Kimberley | ZAP + Azithromycin 1 gram |
| Rest of WA and elsewhere | Azithromycin + Ceftriaxone with lidocaine |
| Uncomplicated urogenital or pharyngeal chlamydia | Goldfields, Kimberley, Pilbara | Azithromycin 1 gram |
| Rest of WA and elsewhere | refer to a prescriber2 |
| Uncomplicated asymptomatic rectal chlamydia | Goldfields, Kimberley, Pilbara | Azithromycin 2 grams2 |
| Rest of WA and elsewhere | refer to a prescriber2 |
| Infectious syphilis | Anywhere | Benzathine benzylpenicillin |
| Asymptomatic sexual partners of confirmed cases | Chlamydia | Goldfields, Kimberley, Pilbara | Azithromycin 1 gram |
| Rest of WA and elsewhere | refer to a prescriber2 |
| Gonorrhoea | Goldfields, Kimberley | ZAP |
| Rest of WA and elsewhere | LAC |
| Infectious syphilis | Anywhere | Benzathine benzylpenicillin |

2 Note: Doxycycline for chlamydia and azithromycin 2 grams, where the medicine is supplied to take home for administration at a later time, **must** be prescribed by an authorised prescriber (medical practitioner or nurse practitioner) and either supplied by the prescriber or dispensed at a pharmacy. This SASA does not authorise Aboriginal Health Practitioners to supply medicines for administration later by the patient.

**Treatment notes**

* Consent to treatment should be obtained, as required, in accordance with local organisational policy.
* Clients should be of advised of expected adverse events and provided with a treatment fact sheet - <http://ww2.health.wa.gov.au/Patient-fact-sheets>.
* For clients with a history of allergy to any component of treatment, or other contraindication - do not administer treatment - seek further advice from a medical practitioner.
* For management of any reported adverse events - seek further advice from a medical practitioner.
* Clients should be directly observed while taking oral doses.
* Cases of syphilis of unknown duration are to be referred to a medical practitioner for ongoing, individual management after the first dose of benzathine benzylpenicillin has been administered.

1. Note: 900 mg benzathine benzylpenicillin = 1,200,000 units = 1016.6 mg benzathine benzylpenicillin tetrahydrate [↑](#footnote-ref-1)